Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure

European Journal of Heart Failure

Volumn 2, Issue 1, 2000, Pages 107-112

  Witte, Klaus ^a   Thackray, Simon ^a   Banerjee, Tumpa ^a   Clark, Andrew L ^a   Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; METOPROLOL; OMAPATRILAT; WARFARIN;

CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; DRUG EFFICACY; HEART FAILURE; HUMAN; KINESIOTHERAPY; METHODOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; EXERCISE TOLERANCE; HEART FAILURE, CONGESTIVE; HUMANS; LOSARTAN; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; THIAZEPINES;

EID: 0034115760     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(00)00053-2     Document Type: Review

References (25)

1. Pitt B., Poole-Wilson P.A., Segal R. et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II. J Card Fail. 5:1999;146-154.
2. Pitt B., Segal R., Martinez F.A. et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet. 349:1997;747-752.
3. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med. 325:1991;293-302.
4. Crozier I., Ikram H., Awan N. et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation. 91:1995;691-697.
5. McElvie R.S., Yusuf S., Pericak D. et al. Comparison of Candesartan, Enalapril and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 100:1999;1056-1064.
6. Cleland J.G.F., Alamgir F. Angiotensin II receptor blockers for heart failure: the current state of play. McMurray J.J.V., Cleland J.G.F. Heart failure in clinical practice. 1999;197-224 Dunitz, London.
7. Swedberg K., Pfeffer M., Granger C. et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail. 5:1999;276-282.
8. Design of the beta-blocker evaluation survival trial (BEST). Am J Cardiol. 75:1995;1220-1223.
9. Packer M., Bristow M.R., Cohn J.N. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med. 334:1996;1349-1355.
10. The Cardiac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13.
11. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 333:1999;2001-2007.
12. McGowan J., Murphy R., Cleland J.G.F. Carvedilol for heart failure; clinical trials in progress. Heart Fail Rev. 4:1999;89-95.
13. Lechat P., Packer M., Chalon S. et al. Clinical effects of α-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind placebo-controlled, randomised trials. Circulation. 98:1998;1184-1191.
14. Heidenreich P.A., Lee T.T., Massie B.M. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomised trials. J Am Coll Cardiol. 30:1997;27-34.
15. Cleland J.G.F., Freemantle N., McGowan J. et al. The evidence for beta-blockers equals or surpasses that for ACE inhibitors in heart failure. Br Med J. 318:1999;824-825.
16. Freemantle N., Cleland J.G.F. et al. What is the place of beta-blockade in secondary prevention after myocardial infarction in the late 1990's. Br Med J. 318:1999;1730-1737.
17. Cleland J.G.F., Bulpitt C.J., Falk R.H. et al. Is aspirin safe for patients with heart failure? Br Heart J. 74:1995;215-219.
18. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. New Engl J Med. 323:1990;147-151.
19. Packer M., Poole Wilson P.A., Armstrong P.W. et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 100:1999;2312-2318.
20. Cleland J.G.F., Swedberg K. on behalf of the International ecadotril multi-centre dose-ranging study investigators. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lancet. 351:1998;1657-1658.
21. Cleland JGF, Armstrong PW, Horowitz JD et al. Baseline characteristics of patients recruited into the assessment of treatment with lisinopril and survival study (ATLAS). Eur J Heart Failure 1999:1.
22. Motwani J.G., Lang C.C., Allen M.J. et al. Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure. Clin Pharmacol Ther. 54:1993;661-669.
23. Good J.M., Peters M., Wilkins M. Renal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol. 25:1995;1273-1281.
24. Cleland JGF. Chronic hemodynamic effects of candoxatril: a multi-centre dose ranging study. J Am Coll Cardiol 1997;29 Suppl A:169A(Abstract).
25. Newby DE, McDonagh T, Currie PF et al. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. J Am Coll Cardiol 1997;29 Suppl A:169A(Abstract).